Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
From Aug RNS The Company's forecast production guidance for FY17 is increased to between 35,000 to 40,000 ounces of gold at operating cash costs of between US$800 to US$900 per ounce. This represents an improvement compared to last year’s delivered results and guidance (30-35 koz at US$850-950/oz operating cash costs), as the Company expects to benefit from the savings generated by the ongoing optimization of operations as well as higher grades from the San Gregorio West Underground project (“SGW UG Project”). So I expecting minimum $300oz x 10000 for this quarter (always over-deliver) converted into £s £2.5m quarter - £10m year into orosur bank plus loads of news on the other projects, no debt! Gold holding $1250oz 100m shares, loads held by institutions. 17th October seems to be Q1 results day
If you follow the paper trail...... Massive gains here if you can buy any!
Dr Stephen Franklin talking at the share investor evening about Evgen Pharma last month, nice to here him reiterate that EVG are fully funded for phase ll trials. Breat cancer trials starting soon adding to SAH Subarachnoid Haemorrhage. https://youtu.be/vloQ-N-D8sY
Of interest how often does a phase ll trial have backing to administer without consent? Patients will be dosed within 48 hours of experiencing SAH and approval has also been obtained in this study to provide for emergency dosing prior to consent. The primary endpoints include safety, pharmacokinetics and efficacy.
Evgen Pharma has unlocked the therapeutic potential of sulforaphane by overcoming this instability. Via its patented Sulforadex® technology, Evgen Pharma is able to synthesise a stable version of sulforaphane in a solid-form complex for delivery either as a capsule or tablet. The lead product, SFX-01, has successfully completed Phase I trials, and proceeds from the IPO in October 2015 are now being used to advance SFX-01 through two Phase II clinical trials: STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) and SAS (SFX-01 After Subarachnoid Heamorrhage). SFX-01 is also currently being tested in preclinical models of multiple sclerosis in a direct head-to-head comparison with Biogen’s BG-12 (marketed as Tecfidera®, with annualised sales currently at $4bn).
More from Sharepickers today on Evgen https://www.voxmarkets.co.uk/blogs/468-berkeley-energy-and-highland-natural-resources/ Today's stock pick CEO is presenting on 17th May at an investor evening https://www.eventbrite.co.uk/e/beaufort-investor-evening-bristol-17th-may-2016-registration-24644704976
Serious company here, they raised £2m pre ipo and £7m on ipo 37p valued Evgen at £27m over subcribed They are the first company to synth sulforaphane, brand it as Sulforadex now in manufacture by PharmAgra to start phase ll of clinical trials, expect news flow anytime now. Its not a brand new drug so has the potential to miss phase lll and get licensed earlier. In an interview with Sharepickers Justin the company said it was 'cashed up' to the end of the journey to take Sulforadex to commercial sales. 73.2m shares and 72% owned by institutions and board, 3 directors bought more this year RNS earlier this year states clinical trials under way in Q2
Firstly I'm in here not heavy just reviewing yesterday The 2.30pm RNS suspension was released by the FCA note temporary suspension at request of the company. The 2.36pm RNS was the company letting us know they had applied for temporary suspension pending announcement. So have we had an announcement yet? No and it's only temporary!
This is high stakes poker with lenders, after all bricks mortar holds coin ££
Way I saw it, was 70/30 to fail, anyway lost a bit of ca$h in here. Maybe being a main market listing we will see some value again? Maybe next year or maybe now the hammers come down a fresh start in sorting out all the mess. Can't see how II have bailed on such a low SP? At least it's not oil and a duster, always value in bricks n mortar Check back in a couple months
Sneaked in 500k top up gulp!
I'm quite happy having these nbr is a perfect shell with a few assets no debt clean company that's lost its way
Oil company in Republic of Congo?
Wonder if Mike and Dave have been under contractual obligation to goshawk not to get the copper project started for a limited time? Taken from August 2014 The slow progress on expansion is very much to be regretted. However, with the cancellation of the Southern Goshawk agreement and the direct involvement of the South African based directors, I believe that the Company is now well placed to move forward. In addition to coal projects, the directors are evaluating a small copper project in Northern Cape Province, South Africa, which could bring early positive cash flow as well as providing a stepping stone to other copper projects in that area.
Sorry pal I'm solo here bought small amount on the back of the two 500k trades last week I was in back in march for a few weeks. Had a few hrs studying NBR high risk high reward n all that
NBR just to look at what could happen here 13m shares available take out the 2x500k buyer last week, only a guess as how many held considerably higher than 2p, maybe £80k buys the free float, just look how quick it moves. Brian Moritz is no mug huge holding add in Dave Johnson and Mike Solomon who joined after the j&j deal was cancelled. They were the ones who was going to steer NBR onto the copper/coal projects through goshawk resources( j&j subsiduary) any hint of a deal this will rocket with such a low mcap. Been ticking over keeping it a nice clean AIM company with £300k worth of assets. Brian Moritz took the reigns after Lord Shepard health failed last year, he is an expert at bringing mining companies through floatation into the market Watch this space!
If you look at the share price over the last few years it was many times higher than now (from 2004) at one point it hit 50p, so assuming there must be many shares bought and held a lot higher than now. It's only the last few months that has seen a fall to this level. Now the interesting part is basically how many are available: Brian Moritz 27.77% Lord Sheppard 29.77% W B nominees 22.92% Not in public hands 18.37% Note: W B nominees is minus Lord Sheppards holding. So from 86,998,615 total shares there is only 13,151,934 No wonder this moves fast, and who knows how many of the 13m shares are collecting cobwebs over the years?
Just taken another look, seems to me we had a 500k buyer early on, difference between the two trades is 11% which would of put this smack bang on the risers board at 09.45 this morning. Then a few PI jumped on which put the rise up to high 30% before it dried up. Add in the 250k buy maybe? Question why did the PI hangers on sell with a loss, why hasn't the 2x500k buyer jumped aswell? Instant profit? Done some digging this evening after shareholders on the board holdings I calculate open market less than 20m shares, no wonder it moves quick when most shares are held 2p higher NBR has been going years, this is the lowest it's been. See it was in pump dump cycle 3 months ago but seems to have settled until today, NBR calendar suggests a news/update must be soon, worth a small investment? Brian moritz and the last ceo hold nearly 50% between them.